What does this research mean for the field?

Upadacitinib can successfully treat refractory cutaneous Crohn's disease. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To report the effectiveness of upadacitinib in treating refractory cutaneous Crohn's disease.

June 3, 2026JAAD Case ReportsOpen Access

Successful treatment of refractory cutaneous Crohn’s disease with upadacitinib: A case report

View Full Paper

Ask AI

Bookmark

Authors

CNChristiaan H NootUniversity of Utah EBEmily P. BeckUniversity of Utah JCJennie T. ClarkeUniversity of Utah Hospital

Discussion

Member takes

Implication

Case report highlights successful resolution of cutaneous symptoms in Crohn’s disease with upadacitinib, suggesting a promising treatment option.

Key Points

To report the effectiveness of upadacitinib in treating refractory cutaneous Crohn's disease.
Described a case of a patient with refractory cutaneous Crohn’s disease treated with upadacitinib.
Monitored symptoms and response to treatment over a defined period.
Significant improvement in cutaneous lesions was observed after initiating upadacitinib therapy.
No serious adverse events were reported during the treatment period.

Cite This Study

Noot et al. (2026) studied this question.

synapsesocial.com/papers/6a63953450e2b8a4ef6ac502 https://doi.org/10.1016/j.jdcr.2026.05.061

View Full Paper

Ask AI

Bookmark

Implication

Case report highlights successful resolution of cutaneous symptoms in Crohn’s disease with upadacitinib, suggesting a promising treatment option.

Successful treatment of refractory cutaneous Crohn’s disease with upadacitinib: A case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Successful treatment of refractory cutaneous Crohn’s disease with upadacitinib: A case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider